Has the Swedish Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 6.0x.

Which industries have driven the changes within the Swedish Healthcare industry?

There are no additional sub-industries under this industry.

Swedish (OMX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 28 May 2026	SEK 250.1b	SEK 38.4b	-SEK 6,184,917,277.94	39.2x	-40.4x	6.5x
Sat, 25 Apr 2026	SEK 231.7b	SEK 38.5b	-SEK 5,560,683,182.71	17.3x	-41.7x	6x
Mon, 23 Mar 2026	SEK 209.0b	SEK 38.5b	-SEK 5,643,801,998.73	16.9x	-37x	5.4x
Wed, 18 Feb 2026	SEK 229.1b	SEK 38.7b	-SEK 5,468,979,713.13	28.7x	-41.9x	5.9x
Fri, 16 Jan 2026	SEK 233.8b	SEK 38.1b	-SEK 556,295,627.21	40.4x	-420.3x	6.1x
Sun, 14 Dec 2025	SEK 205.5b	SEK 38.1b	-SEK 604,523,623.92	31.3x	-340x	5.4x
Tue, 11 Nov 2025	SEK 201.0b	SEK 37.3b	-SEK 1,181,866,250.41	37.4x	-170.1x	5.4x
Thu, 09 Oct 2025	SEK 207.4b	SEK 36.4b	SEK 3.1b	32.3x	67x	5.7x
Sat, 06 Sep 2025	SEK 196.9b	SEK 36.4b	SEK 3.1b	30.4x	64.5x	5.4x
Mon, 04 Aug 2025	SEK 184.2b	SEK 35.9b	SEK 2.8b	27.3x	66x	5.1x
Wed, 02 Jul 2025	SEK 185.4b	SEK 35.2b	SEK 2.3b	29.8x	80.6x	5.3x
Fri, 30 May 2025	SEK 186.1b	SEK 35.2b	SEK 2.2b	29.8x	82.8x	5.3x
Sun, 27 Apr 2025	SEK 183.3b	SEK 33.7b	SEK 801.8m	29.1x	228.5x	5.4x
Tue, 25 Mar 2025	SEK 192.3b	SEK 33.7b	SEK 724.0m	32.5x	265.6x	5.7x
Thu, 20 Feb 2025	SEK 213.3b	SEK 33.3b	SEK 346.5m	45.4x	615.5x	6.4x
Sat, 18 Jan 2025	SEK 220.3b	SEK 33.0b	-SEK 4,418,544,857.77	152.7x	-49.9x	6.7x
Mon, 16 Dec 2024	SEK 212.2b	SEK 33.0b	-SEK 4,445,592,850.19	144.8x	-47.7x	6.4x
Wed, 13 Nov 2024	SEK 213.9b	SEK 33.2b	-SEK 4,389,945,860.24	144.4x	-48.7x	6.4x
Fri, 11 Oct 2024	SEK 205.9b	SEK 31.4b	-SEK 5,535,963,629.20	47.5x	-37.2x	6.5x
Sun, 08 Sep 2024	SEK 212.4b	SEK 31.5b	-SEK 5,571,250,522.59	49.2x	-38.1x	6.8x
Tue, 06 Aug 2024	SEK 186.1b	SEK 31.4b	-SEK 5,420,584,602.86	41.8x	-34.3x	5.9x
Thu, 04 Jul 2024	SEK 191.7b	SEK 30.6b	-SEK 5,537,333,555.67	38.4x	-34.6x	6.3x
Sat, 01 Jun 2024	SEK 198.4b	SEK 30.6b	-SEK 5,725,690,180.58	39.8x	-34.7x	6.5x
Mon, 29 Apr 2024	SEK 183.9b	SEK 30.8b	-SEK 5,612,153,350.26	50.9x	-32.8x	6x
Wed, 27 Mar 2024	SEK 185.9b	SEK 29.8b	-SEK 5,637,426,016.82	61.5x	-33x	6.2x
Fri, 23 Feb 2024	SEK 182.1b	SEK 29.7b	-SEK 5,686,647,248.71	52.7x	-32x	6.1x
Sun, 21 Jan 2024	SEK 186.9b	SEK 28.7b	-SEK 1,200,602,862.00	57.4x	-155.6x	6.5x
Tue, 19 Dec 2023	SEK 180.9b	SEK 28.7b	-SEK 1,169,941,500.00	59.7x	-154.7x	6.3x
Thu, 16 Nov 2023	SEK 166.4b	SEK 28.7b	-SEK 1,230,832,373.00	51.2x	-135.2x	5.8x
Sat, 14 Oct 2023	SEK 154.5b	SEK 27.4b	-SEK 1,962,955,624.00	48.8x	-78.7x	5.6x
Mon, 11 Sep 2023	SEK 150.4b	SEK 27.4b	-SEK 1,977,547,540.00	47x	-76.1x	5.5x
Wed, 09 Aug 2023	SEK 155.6b	SEK 27.5b	-SEK 1,576,205,416.00	53.3x	-98.7x	5.6x
Fri, 07 Jul 2023	SEK 160.4b	SEK 26.4b	-SEK 1,278,793,132.00	46.6x	-125.4x	6.1x
Sun, 04 Jun 2023	SEK 168.1b	SEK 26.4b	-SEK 1,242,510,092.00	45.5x	-135.3x	6.4x


SE Market	1.32%
Healthcare	0.80%
Biotech	0.64%
Biotech	0.64%

Company	Last Price	7D	1Y	Valuation
SOBI Swedish Orphan Biovitrum	SEK 444.00	1.7% +SEK 2.6b	51.2%	PE166.7x
BIOA B BioArctic	SEK 340.40	5.8% +SEK 1.7b	94.1%	PE141.6x
BINV BioInvent International	SEK 29.85	15.7% +SEK 266.5m	-19.3%	PS9x
VICO Vicore Pharma Holding	SEK 11.82	7.3% +SEK 225.2m	42.6%	PS943.5x
HNSA Hansa Biopharma	SEK 35.18	4.8% +SEK 162.8m	51.0%	PS18.8x

Announcement • 10h

Hansa Biopharma Announces Late-Breaking Abstract from Confides Phase 3 Trial Selected for Oral Presentation At ATC 2026

Hansa Biopharma AB (publ) Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026. Highly sensitized patients have pre-formed antibodies called donor specific antibodies (DSAs) with a broad reactivity against human leukocyte antigens (HLAs), which can cause tissue damage and potentially transplant rejection.1 The presence of DSAs means that highly sensitized patients tend to have limited or no access to transplant, as finding a compatible donor organ can be particularly challenging.2,3 The complexity of their immunological profile means that highly sensitized patients spend longer time than average on transplant waiting lists, with evidence showing that this longer time waiting for a suitable donor relates to an increased mortality risk.4,5 Across the U.S. and Europe, highly sensitized patients comprise around 10%-15% of the total of patients on transplant waiting lists.6,7AboutimlifidaseImlifidase is conditionally approved in the European Union, Norway, Liechtenstein, Iceland and the UK under the tradename IDEFIRIX® for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. IDEFIRIX® is also approved in Australia, Israel and Switzerland. Information about the trial is available at ClinicalTrials.gov:NCT04935177About IDEFIRIX® (imlifidase) Imlifidase is an antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets and cleaves immunoglobulin G (IgG) antibodies and inhibits IgG-mediated immune response.8 It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. Imlifidase has conditional marketing approval in Europe and is marketed under the trade name IDEFIRIX for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The use of IDEFIRIX should be reserved for patients who are unlikely to be transplanted under the available kidney allocation system, including prioritization programs for highly sensitized patients.8 IDEFIRIX was reviewed as part of the European Medicines Agency's (EMA) PRIority Medicines (PRIME) program, which supports medicines that may offer a major therapeutic advantage over existing treatments or benefit patients without treatment options.8The efficacy and safety of imlifidase as a pre-transplant treatment to reduce donor-specific IgG antibodies was studied in four phase 2 single-arm, studies in EU and US as well as a randomized, controlled Phase 3 study in US.5,7,10-11 Hansa is collecting further clinical evidence and will submit additional efficacy and safety data based on one observational follow-up study and one post-approval efficacy study. In the US, the Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for imlifidase in February of 2026 and assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026.Full EU product information can be accessed via the initial Summary of Product Characteristics foundhere. About kidney failure Kidney disease can progress to kidney failure or End-Stage Renal Disease (ESRD), identified when a patient's kidney function is less than 15%.12 ESRD poses a significant health burden, affecting nearly 2.5 million patients worldwide.12 A kidney transplant is the treatment of choice for suitable patients with ESRD because it offers improved survival and quality of life benefits, and is cost savings compared to long-term dialysis. There are approximately 170,000 kidney patients in the U.S. and Europe waiting for a new kidney.

Announcement • 16h

Swedish Orphan Biovitrum AB Announces Results From New Analysis Of Tryngolza Phase 3 CORE And CORE2 Trials

Swedish Orphan Biovitrum AB announced results from a new analysis of the pivotal Phase 3 CORE and CORE2 trials, showing Tryngolza (olezarsen) reduced the relative risk of acute pancreatitis events by 85% (P<0.001) and reduced triglycerides by 66% in patients with severe hypertriglyceridemia (sHTG) after six months. The pooled subgroup analysis, presented as a late breaking abstract at the European Atherosclerosis Society (EAS) 2026 Congress in Athens, Greece, included 455 patients with baseline triglycerides of =880 mg/dL (~10 mmol/L), defined by the EAS as severe hypertriglyceridemia. At six months, patients randomised to receive olezarsen 80 mg showed a placebo-adjusted reduction in triglycerides of 66%, and those on olezarsen 50 mg a 59% reduction (each P<0.001). Overall, 85% of olezarsen-treated patients achieved triglycerides of <10 mmol/L. Severe hypertriglyceridemia is the third most common cause of acute pancreatitis. The incidence of acute pancreatitis globally has increased at an average annual rate of 3% since the 1960s, contributing to a growing burden on healthcare systems. The results, presented by Dr Andre Zimerman on behalf of the TIMI Study Group, showed olezarsen 80 mg and 50 mg also reduced remnant cholesterol by 64% and 53%, respectively, and non-HDL-C by 35% and 27%. The absolute reduction in pancreatitis events with olezarsen was 12 per 100 patient-years, meaning treating nine patients over one year would prevent one acute pancreatitis event in the type of patients included in the study. The safety profile in the subgroup analysis was favourable and similar to the broader trial population. In March 2026, the European Medicines Agency validated an indication extension application for olezarsen for the treatment of adults with sHTG and triglyceride levels =880 mg/dL (~10 mmol/L), aligned with EAS guidelines. In February 2026 the U.S. FDA accepted for Priority Review a supplemental New Drug Application for olezarsen for sHTG (triglyceride levels =500 mg/dL), with a target action date of June 30, 2026. Olezarsen is developed by Ionis Pharmaceuticals. Sobi and Ionis entered into a license agreement under which Sobi has exclusive rights to commercialise Tryngolza in ex-U.S. geographies except Canada and China. Severe hypertriglyceridemia (sHTG) is defined by severely high triglyceride levels =500 mg/dL (=5.65 mmol/L) and triglyceride levels =880 mg/dL (~10 mmol/L) are often associated with the increased accumulation of chylomicrons in the blood and with an increased risk of acute pancreatitis and other morbidities. Considered a medical emergency, acute pancreatitis causes debilitating abdominal pain that often requires prolonged hospitalisation, can lead to permanent organ damage and can become life-threatening. Preventing the first pancreatitis event is key. Current standard of care therapies for sHTG and lifestyle modifications (such as diet and exercise) do not sufficiently or consistently lower triglyceride levels or reduce the risks in all patients. Approximately 2 million people are living with sHTG in the EU5, including approximately 700,000 with TG levels =880 mg/dL (~10 mmol/L). CORE (NCT05079919; n=617) and CORE2 (NCT05552326; n=446), conducted with The TIMI Study Group, were Phase 3 global, multicentre, randomised, double-blind, placebo-controlled trials investigating the safety and efficacy of olezarsen for sHTG. Participants aged 18 years and older with triglyceride levels =500 mg/dL (5.65 mmol/L) were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 43% of participants had fasting triglycerides =880 mg/dL (~10 mmol/L). Participants were randomised to receive 50 mg or 80 mg of olezarsen or placebo every 4 weeks via subcutaneous injection for 12 months. The primary endpoint was the percent change from baseline in fasting triglycerides at six months compared to placebo. Olezarsen is an RNA-targeted medicine being evaluated for the treatment of severe hypertriglyceridemia. Olezarsen is designed to lower the body's production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. Olezarsen is approved in the U.S., European Union, and other countries as TRYNGOLZA for adults with familial chylomicronemia syndrome (FCS).

Swedish (OMX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Is SynAct Pharma (STO:SYNACT) In A Good Position To Deliver On Growth Plans?

BioArctic's (STO:BIOA B) Soft Earnings Don't Show The Whole Picture

Investor sentiment deteriorates as stock falls 16%

Hansa Biopharma Announces Late-Breaking Abstract from Confides Phase 3 Trial Selected for Oral Presentation At ATC 2026

Swedish Orphan Biovitrum AB Announces Results From New Analysis Of Tryngolza Phase 3 CORE And CORE2 Trials

Bonesupport Holding Sees Rapid Earnings Growth and Strong Insider Ownership in 2026

First quarter 2026 earnings released: kr0.33 loss per share (vs kr0.17 profit in 1Q 2025)

BIOG B: Margin Resilience And LongevityGuard Technology Will Support Future Re Rating

Hamlet Biopharma Secures New Patents and Allowances

High number of new directors

New minor risk - Shareholder dilution

VITR: Governance Reforms And Higher P/E Expectations Will Support Future Upside Potential

Diamyd Medical AB (publ) Provides Update on Strategic Review and Clinical Development Plans

New minor risk - Shareholder dilution

New major risk - Financial position

New minor risk - Profitability